Zoltán J. Taybani, Hungary
Békés County Central Hospital, Dr. Réthy Pál Member Hospital 1st Department of EndocrinologyPresenter of 1 Presentation
ONE-YEAR SAFETY AND EFFICACY OF INSULIN-THERAPY SIMPLIFICATION WITH IDEGLIRA IN TYPE 2 DIABETES
Abstract
Background and Aims
Multiple daily insulin injection (MDI) regimens in type 2 diabetes (T2D) can provide optimal glycemic control but cause significant treatment burden, hence simpler therapies with similar efficacy are needed. Our preliminary 3-month follow-up data showed that switching from MDI to once daily IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, in relatively well-controlled (HbA1c<7.5%) subjects with T2D using low total daily insulin dose is safe and provides similar or better glycemic control. Our aim was to confirm the sustained efficacy and safety of the simplified treatment during a 12-month follow-up.
Methods
72 adults with T2D (mean±SD: age 63.8±9.5 years, HbA1c 6.36±0.70%, BMI 33.01±6.47kg/m2, body weight 92.95±18.83kg, total daily insulin dose: 43.2±10.8 units, duration of diabetes 9.7±7.5 years) treated with MDI±metformin participated in our study. Previous insulins were stopped and once daily IDegLira was started. IDegLira was titrated by the patients every 3 days with 2 dosage units to achieve a self-measured pre-breakfast plasma glucose concentration of <6mmol/L.
Results
After 12-month of follow-up good glycemic control was maintained, while body weight and BMI decreased significantly. Mean HbA1c changed by -0.15% to 6.21±0.82% (p= 0.109), body weight changed by -3.89kg to 89.06±18.61kg (p<0.0001) and BMI changed to 31.61±6.22kg/m2. The simplified treatment was safe and well-tolerated. Percentage of patients experiencing hypoglycemia was 49% during the month before simplification and 17% during the last 3 months of the follow-up.
Conclusions
Our 12-month data confirm that insulin-therapy simplification with IDegLira in patients with well-controlled T2D is safe, may induce weight loss and results in similar glycemic control.